Section Arrow
ANVS.NYSE
- Annovis Bio
Quotes are at least 15-min delayed:2026/08/10 17:46 EDT
After Hours
Last
 1.8468
-0.0432 (-2.29%)
Bid
1.84
Ask
1.89
High 1.89 
Low 1.8468 
Volume 262 
Regular Hours (Closed)
Last
 1.89
+0.01 (+0.53%)
Day High 
1.9 
Prev. Close
1.88 
1-M High
2.17 
Volume 
321.13K 
Bid
1.84
Ask
1.89
Day Low
1.85 
Open
1.9 
1-M Low
1.55 
Market Cap 
79.98M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 1.78 
20-SMA 1.76 
50-SMA 1.8 
52-W High 5.5 
52-W Low 1.5407 
Exchange NYSE 
Valuation Estimation
EPS (Current/Estimated)
-1.71/-1.24
Enterprise Value
80.48M
Balance Sheet
Book Value Per Share
0.07
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
TENXTenax Therapeutics1.375-12.065-89.77%-- 
After Hours 1.4199 +0.0449 +3.27%
ABCLAbCellera Biologics9.34+2.41+34.78%-- 
After Hours 9.21 -0.13 -1.39%
SIONSionna Therapeutics Inc4.5-46.54-91.18%-- 
After Hours 4.39 -0.11 -2.44%
IOVAIovance Biotherapeutics6.4+0.06+0.95%-- 
After Hours 6.4299 +0.0299 +0.47%
GOSSGossamer Bio0.1761-0.0019-1.07%-- 
After Hours 0.177 +0.0009 +0.51%
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Annovis Bio Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's flagship candidate, buntanetap, is in clinical trials for the treatment of Alzheimer's disease, Parkinson's disease, and Lewy body dementia. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.